Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Colonic Neoplasms × regorafenib × Clear all

Phase

Status

Sponsor Class

OTHER 10 INDUSTRY 3 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 2 Carcinoma 2 Adenocarcinoma 2 Sarcoma, Ewing 1 Gastrointestinal Stromal Tumors 1 Colonic Neoplasms 1

Interventions

Fluorouracil 20 Leucovorin 18 Oxaliplatin 11 Irinotecan 10 Capecitabine 6 Bevacizumab 5 Cetuximab 4 Levamisole 3 Celecoxib 3 cediranib 2 Watchful Waiting 2 Tegafur 2 Surveys and Questionnaires 2 Psychiatric Rehabilitation 2 Folfox protocol 2 Counseling 2 Cisplatin 2 tumor necrosis factor-alpha, CNGRC fusion protein, human 1 tipifarnib 1 regorafenib 1 pertuzumab 1 olaparib 1 mercaptoundecahydrododecaborate 1 gevokizumab 1 eniluracil 1 cemiplimab 1 brivanib 1 alpha-Tocopherol 1 Vitamin E 1 Uracil 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02664077 2022-04-14

ARGO

NSABP Foundation Inc

Phase 3 Terminated

Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡